Normax raises €300m in pre-IPO capital to scale vaccine production and target a public listing
The pre-IPO financing comes from a cornerstone investor to support affordable mRNA vaccine development and modular manufacturing.
≈ £259M at €1 = £0.8617 on 30 Jun 2022
Normax is an Irish biotechnology firm focused on developing and manufacturing affordable mRNA vaccines to combat infectious diseases.
Irish biotechnology company Normax has secured €300m in pre-IPO capital to advance its manufacturing capabilities and prepare for a public listing.
The funding will support the development of affordable pan-Coronavirus mRNA vaccine boosters as well as research for tuberculosis, HIV, and malaria. Normax also plans to construct five modular manufacturing facilities, with the initial site slated for Cork.
The firm intends to list its shares on both the London Stock Exchange and the SIX Swiss Exchange, alongside digital listings on the SIX Digital Exchange.
From the founder
"Normax is on a social mission to redress global healthcare inequity caused by the profiteering pharmaceutical industry. Following the recent €300 million capital commitment in Normax, we plan to deliver research and development of mRNA vaccines for COVID, TB, HIV, and Malaria and deploy modular mRNA Vaccine Factories, ultimately in up to 100 locations. In the event of another public health emergency we are also committed to delivering future mRNA vaccines in 100 days, to help ensure that COVID-19 is the last pandemic we will all suffer through,"
Peter Jensen
CEO and Chairman at Normax
Use of funds
- 01Fund research and development
- 02Build out infrastructure